South Korea-based biomedicine maker Samsung Biologics has unveiled plans to build its fourth plant this year to boost its manufacturing capabilities.
Once complete, the 256kl plant in Incheon will increase the company’s total capacity to 620kl. Manufacturing operations are expected to start in the second half of 2022.
Samsung Biologics will design the plant by incorporating unique features of the three previous plants to enable multi-scale manufacturing services at the site.
Plant 4 will comprise a total floor area of 23.8 million square metres.
Samsung Biologics CEO Dr Tae Han Kim said: “In this continuously evolving climate, we are strategically positioning ourselves to respond to the needs of our global clients who are producing new medicines that are more complex and diverse and deliver superior client satisfaction.
“With the production of Plant 4, our ‘Super Plant,’ Samsung Biologics is investing in a total line refinement and addition of new mid-scale and small-scale facilities to ensure production efficiency and provide top-notch services to raise the bar even further to establish ourselves as the leading global standard.”
The company also announced that it entered negotiations with Incheon Free Economic Zone (IFEZ) authorities to acquire additional land for its second bio complex.
Samsung Biologics will develop a global R&D facility and an open innovation centre on a 330,000m² area near the company’s current complex.
Overall, Samsung Biologics could invest more than KRW2trn ($2bn) on the two initiatives.
In May, GlaxoSmithKline signed an agreement with Samsung Biologics to increase capacity to manufacture and supply its biopharmaceutical therapies.